APEN - APEN STOCK NEWS

Apollo Endosurgery (NASDAQ: APEN) announced a public offering of its common stock. The company aims to use the proceeds to expand sales and marketing efforts, enhance product offerings, and refinance existing debt. The offering will be made under a previously filed shelf registration statement. The underwriters have a 30-day option to purchase additional shares. While Apollo seeks to enhance growth through this capital raise, the offering's completion depends on market conditions.

Apollo Endosurgery (NASDAQ:APEN) announced preliminary financial results for Q3 2021, projecting revenue between $16.0 million and $16.4 million, reflecting a 25% to 28% growth from the previous year. This marks the company's third consecutive quarter of double-digit growth, with endoscopic suturing revenues up over 30%. The company has submitted a De Novo 510(k) request to the FDA for its Apollo ESG™ and Apollo REVISE™ devices, critical for weight loss and bariatric revisions. Final results will be disclosed on November 1, 2021.

Apollo Endosurgery, a leader in less invasive medical devices, will participate in Lake Street's 5th Annual Best Ideas Growth Conference on September 14-15, 2021. This virtual event will feature management teams from over 100 small-cap public companies engaging with 300 institutional investors. Apollo offers innovative therapies for gastrointestinal issues and obesity, marketed in over 75 countries. Investors can reach out to Lake Street representatives or Apollo's investor relations for attendance and meeting arrangements.

Apollo Endosurgery reported strong financial results for Q2 2021, achieving total revenue of $16.6 million, a remarkable 194% increase from Q2 2020. This growth is attributed to a 196% rise in Endoscopic Suturing System (ESS) sales and a 220% increase in Intragastric Balloon (IGB) sales. The company's gross margin improved to 55%. Apollo also expanded its X-Tack user base to over 120 active sites and announced positive results from the MERIT study. The company raised its full-year revenue guidance to $61-$63 million.

Apollo Endosurgery, a leader in minimally invasive medical devices, will release its Q2 2021 financial results on August 3, 2021, after market close. A conference call is scheduled at 3:30 p.m. CT to discuss the results. The company focuses on innovative solutions for gastrointestinal conditions, with products available in over 75 countries. Apollo emphasizes the importance of their device-based therapies in reducing healthcare costs and complication rates.

Apollo Endosurgery has appointed Jeffrey G. Black as its new Chief Financial Officer, effective immediately after the quarterly filing for June 30, 2021. Black brings 30 years of financial leadership in medical technology, including significant roles in companies like Alphatec Holdings and Verenium Corporation. His expertise includes managing over $1 billion in financing and strategic transactions. Previous CFO Stefanie Cavanaugh will remain with the company to assist in scaling operations. This leadership change is expected to support Apollo's growth and innovation in the gastrointestinal medical device market.

Apollo Endosurgery (NASDAQ:APEN) announced the successful preliminary analysis of the MERIT study, which compares the Endoscopic Sleeve Gastroplasty (ESG) procedure to medically supervised lifestyle modifications. The study achieved its primary endpoints for both effectiveness and safety, with results presented by Dr. Barham Abu Dayyeh at the 2021 Surgical Disruptive Technologies Summit. The study aims to provide insights into significant weight loss and improved health outcomes over 24 months. Apollo plans to use these results for potential FDA submissions.

Apollo Endosurgery (Nasdaq:APEN) has announced its participation in two upcoming investor conferences in June 2021. On June 2, management will engage in one-on-one virtual meetings at the 18th Annual Craig-Hallum Institutional Investor Conference. Later, on June 16-17, the team will present at the JMP Securities Life Sciences Conference, with a group presentation scheduled for June 17 at 3:30 PM ET. Apollo is recognized for its innovative, less invasive medical devices aimed at gastrointestinal procedures and operates in over 75 countries.

Apollo Endosurgery (Nasdaq: APEN) highlighted its OverStitch Endoscopic Suturing System at the Digestive Disease Week (DDW) 2021 from May 21-23. Key presentations included the sub-study from the MERIT Trial showing significant weight loss with Endoscopic Sleeve Gastroplasty (ESG), both alone and combined with Semaglutide, with %TBWL up to 26.7%. Additionally, endoscopic procedures demonstrated lower adverse event rates compared to surgical revisions. The ongoing research aims to expand the indications for ESG with FDA collaboration.